Skip to main content

Bronchiolitis Obliterans

4
Pipeline Programs
4
Companies
7
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
4
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Zambon
ZambonItaly - Bresso
3 programs
3
Liposomal Cyclosporine APhase 31 trial
Liposomal Cyclosporine APhase 31 trial
Liposomal Cyclosporine A 5 mgPhase 31 trial
Active Trials
NCT03656926Completed169Est. Mar 2024
NCT03657342Completed62Est. Apr 2024
NCT04039347Terminated164Est. Feb 2026
Eppendorf
EppendorfGermany - Hamburg
1 program
1
TacrolimusPhase 31 trial
Active Trials
NCT01429844Completed274Est. Aug 2010
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
Biospecimen CollectionN/A2 trials
Active Trials
NCT05056857Recruiting290Est. Oct 2026
NCT04604522Recruiting15Est. Mar 2026
TransMedics
TransMedicsANDOVER, MA
1 program
OCS Lung SystemN/A1 trial
Active Trials
NCT03868904Completed220Est. Oct 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ZambonLiposomal Cyclosporine A 5 mg
ZambonLiposomal Cyclosporine A
ZambonLiposomal Cyclosporine A
EppendorfTacrolimus
Allergy TherapeuticsBiospecimen Collection
Allergy TherapeuticsBiospecimen Collection
TransMedicsOCS Lung System

Clinical Trials (7)

Total enrollment: 1,194 patients across 7 trials

NCT04039347ZambonLiposomal Cyclosporine A 5 mg

Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)

Start: Mar 2020Est. completion: Feb 2026164 patients
Phase 3Terminated
NCT03656926ZambonLiposomal Cyclosporine A

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)

Start: Mar 2019Est. completion: Mar 2024169 patients
Phase 3Completed
NCT03657342ZambonLiposomal Cyclosporine A

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)

Start: Mar 2019Est. completion: Apr 202462 patients
Phase 3Completed
NCT01429844EppendorfTacrolimus

Tacrolimus Versus Cyclosporine for Immunosuppression After Lung Transplantation

Start: Jan 2001Est. completion: Aug 2010274 patients
Phase 3Completed
NCT05056857Allergy TherapeuticsBiospecimen Collection

Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking Tamoxifen

Start: Oct 2021Est. completion: Oct 2026290 patients
N/ARecruiting
NCT04604522Allergy TherapeuticsBiospecimen Collection

Evaluating Clonogenic Epithelial Cell Populations in Patients With Bronchiolitis Obliterans Syndrome

Start: Aug 2020Est. completion: Mar 202615 patients
N/ARecruiting
NCT03868904TransMedicsOCS Lung System

INSPIRE Continuation Post-Approval Study

Start: Jun 2019Est. completion: Oct 2021220 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs, potential near-term approvals
2 actively recruiting trials targeting 1,194 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.